BriaCell engaged Charles River Associates to evaluate US epidemiology, pricing and prescriber dynamics for Bria-IMT in metastatic breast cancer, and hired Kaleio for brand strategy and commercial-readiness solutions. These steps coincide with its pivotal Phase 3 trial and aim to advance market access planning pending successful outcomes.
BriaCell engaged Charles River Associates to assess US epidemiology, pricing and prescriber dynamics for Bria-IMT in metastatic breast cancer, and retained Kaleio to develop brand strategies and customized commercial-readiness solutions.
Bria-IMT is currently being evaluated in a pivotal Phase 3 study (NCT06072612) in patients with metastatic breast cancer, targeting safety and efficacy endpoints across multiple US clinical sites ahead of potential regulatory submission.
These consultancy agreements support BriaCell’s market access planning and brand positioning, laying groundwork for pricing strategies, prescriber engagement and commercialization planning in anticipation of positive clinical results and approval.
